Observational studyBMC endocrine disorders2025
Risk factors for progression to albuminuria in individuals with newly diagnosed type 2 diabetes: a 5-year cohort study.
Observational study in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study aimed to determine the 5-year incidence of albuminuria in Chinese individuals with newly diagnosed type 2 diabetes mellitus (T2DM) and identify baseline risk factors for progression to albuminuria.
methodsAn observational cohort study was conducted with 604 individuals aged ≥ 18 years diagnosed with T2DM between January 2014 and December 2017 at a tertiary hospital in China, followed through November 2022. The cumulative incidence of progression from normoalbuminuria to albuminuria was assessed. Risk factors for progression were evaluated using multiple logistic regression.
resultsOf the 368 individuals with normoalbuminuria at diagnosis, the mean (SD) age was 54 (11) years. The 5-year cumulative incidence of progression to albuminuria was 7.9%. Higher urine albumin-to-creatinine ratio (UACR) (OR 1.18; 95% CI, 1.10-1.26) and higher homeostasis model assessment of insulin resistance (HOMA-IR) (OR 1.18; 95% CI, 1.15-1.32) at diagnosis were independently associated with progression. After adjusting for baseline UACR, higher HOMA-IR at diagnosis was linked to a more rapid increase in UACR over time.
conclusionEarly screening for UACR and management of insulin resistance in individuals with T2DM may help delay the onset of microalbuminuria.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.